Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.55 |
| ▸ | NPY1R | P25929 | 12/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.55 |
| ▸ | NPY2R | P49146 | 8/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262648 | 0.87 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4099155 | 0.84 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29947151 | 0.84 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29947137 | 0.84 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL27639946 | 0.84 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29655324 | 0.84 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29947104 | 0.84 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30531637 | 0.83 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4086550 | 0.83 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4257066 | 0.83 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | NPY4R 1014/4885NPY1R 2090/4885NPY5R 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.